GOVERNEUR, N.Y. – Kinney Drugs has now opened both walk-ins and appointments for a second dose of seasonal COVID-19 vaccine for eligible individuals. In October, the CDC recommended that individuals aged 65 and older and those who are moderately to severely immunocompromised receive a second dose of seasonal COVID-19 vaccine two to six months after their last dose.
Patients in one or both groups who were vaccinated against COVID in the fall may now be due for a second dose. Kinney Drugs accepts walk-ins; however, appointments are encouraged to ensure the promptest service. The COVID-19 vaccine can be co-administered with all other approved vaccines.
“CDC data show the importance of vaccination to protect people who are most at risk for severe outcomes of COVID, such as older adults and anyone with an immunocompromising condition,” said John Marraffa, president of Kinney Drugs. “We know that vaccination can restore and enhance protection against those viruses that are causing infections and hospitalizations in our region, including RSV, COVID, and influenza. And flu is spiking right now, especially in older populations. So, if patients haven’t received their flu vaccine, it’s not too late for this year. As always, our pharmacists stand ready to assist with immunizations and other healthcare needs,” he added.
Kinney Drugs expands COVID-19 vaccine access for high-risk individuals
Patients in one or both groups who were vaccinated against COVID in the fall may now be due for a second dose.
Latest
HDA awards McKesson’s Brandon Miller with 2026 DMA for industry leadership
The distributor and manufacturer member executives of the HDA Industry Relations Council select the award winners.
HDA presents 2026 Distribution Management Award To Cardinal Health
Cardinal Health was recognized for a project, “Enhancing DSCSA Transparency Through EDI 852 Quarantine Field Implementation."
Video Forum: Tanvi Patel, Amazon Pharmacy
Helping patients navigate the health care system.
Zepbound’s growth fuels new employer coverage models
The success of Eli Lilly’s Zepbound is encouraging efforts to expand access to obesity treatments by clarifying pricing and reducing costs.